Martin Shaw, Business Development at AroCell, held a presentation on the Thymidine Kinase 1 immunoassay, highlighting its significance as a valuable translational biomarker from drug discovery through to clinical trials. You can see the presentation below.
Presentation of IDL Diagnostics Interim Report Q1 2026
CEO Anders Hultman and CFO Ellen Dittberner present the company’s Q1’26 results – May 13, 2026 Q1 Interview: Redeye talks with CEO Anders Hultman
